SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-052736
Filing Date
2023-11-13
Accepted
2023-11-13 08:12:39
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20014551_8k.htm   iXBRL 8-K 26005
2 EXHIBIT 99.1 ef20014551_ex99-1.htm EX-99.1 173516
6 image001.jpg GRAPHIC 9554
  Complete submission text file 0001140361-23-052736.txt   362926

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ocup-20231113.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20231113_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20231113_pre.xml EX-101.PRE 16044
8 EXTRACTED XBRL INSTANCE DOCUMENT ef20014551_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 231395298
SIC: 2834 Pharmaceutical Preparations